BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 15590181)

  • 1. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease.
    Cheng JC; Wu JK; Lee PC; Liu HS; Jian JJ; Lin YM; Sung JL; Jan GJ
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1502-9. PubMed ID: 15590181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease.
    Cheng JC; Liu HS; Wu JK; Chung HW; Jan GJ
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1150-6. PubMed ID: 15990021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma.
    Xu ZY; Liang SX; Zhu J; Zhu XD; Zhao JD; Lu HJ; Yang YL; Chen L; Wang AY; Fu XL; Jiang GL
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):189-95. PubMed ID: 16542787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy.
    Kim TH; Kim DY; Park JW; Kim SH; Choi JI; Kim HB; Lee WJ; Park SJ; Hong EK; Kim CM
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):225-31. PubMed ID: 17056199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.
    Liang SX; Zhu XD; Xu ZY; Zhu J; Zhao JD; Lu HJ; Yang YL; Chen L; Wang AY; Fu XL; Jiang GL
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):426-34. PubMed ID: 16690430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication.
    Cheng JC; Wu JK; Huang CM; Liu HS; Huang DY; Cheng SH; Tsai SY; Jian JJ; Lin YM; Cheng TI; Horng CF; Huang AT
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):156-62. PubMed ID: 12182986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma.
    Kim JH; Park JW; Kim TH; Koh DW; Lee WJ; Kim CM
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):813-9. PubMed ID: 17524569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapolation of normal tissue complication probability for different fractionations in liver irradiation.
    Tai A; Erickson B; Li XA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):283-9. PubMed ID: 19289259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Zhou ZH; Liu LM; Cheng WW; Meng ZQ; Lin JH; Chen Z; Zhang XJ; Jiang GL
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):222-6. PubMed ID: 16875612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial volume tolerance of the liver to radiation.
    Dawson LA; Ten Haken RK
    Semin Radiat Oncol; 2005 Oct; 15(4):279-83. PubMed ID: 16183482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease.
    Cheng JC; Wu JK; Huang CM; Liu HS; Huang DY; Tsai SY; Cheng SH; Jian JJ; Huang AT
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):229-34. PubMed ID: 12694843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
    Kim TH; Cho KH; Pyo HR; Lee JS; Han JY; Zo JI; Lee JM; Hong EK; Choi IJ; Park SY; Shin KH; Kim DY; Kim JY
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):995-1002. PubMed ID: 15990000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors.
    Thomas E; Chapet O; Kessler ML; Lawrence TS; Ten Haken RK
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):571-8. PubMed ID: 15890602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.
    Piotrowski T; Matecka-Nowak M; Milecki P
    Neoplasma; 2005; 52(1):56-62. PubMed ID: 15739028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma.
    Liang SX; Zhu XD; Lu HJ; Pan CY; Li FX; Huang QF; Wang AY; Chen L; Fu XL; Jiang GL
    Cancer; 2005 May; 103(10):2181-8. PubMed ID: 15812834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J; Heemsbergen W; Hoogeman M; Pengel K; Rossi M; Lebesque J
    Radiother Oncol; 2005 May; 75(2):157-64. PubMed ID: 15890421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
    Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK
    Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reappraisal of risk factors predicting liver complications from radiotherapy for hepatocellular carcinoma].
    Lee IJ; Seong J; Shim SJ; Han KH; Chon CY
    Korean J Hepatol; 2006 Sep; 12(3):420-8. PubMed ID: 16998294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
    J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
    Son SH; Choi BO; Ryu MR; Kang YN; Jang JS; Bae SH; Yoon SK; Choi IB; Kang KM; Jang HS
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1073-80. PubMed ID: 20207492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.